Hu Zhou | Hematology | Excellence in Research Award

Published on by Global Academic Awards

Prof. Dr. Hu Zhou | Hematology | Excellence in Research Award

Henan Cancer Hospital | China

Prof. Dr. Hu Zhou is a leading hematology researcher recognized for his extensive work on the pathogenesis and clinical management of blood disorders, particularly immune thrombocytopenia, myelodysplastic syndromes, myeloproliferative neoplasms, and thrombosis–hemostasis abnormalities. With 621 citations, 78 published documents, and an h-index of 14, he has established a strong scholarly footprint in clinical and translational hematology. His research integrates clinical trials, molecular pathology, and mechanistic studies, contributing significantly to advances in immunoglobulin therapies, monoclonal antibodies, JAK2 inhibitors, and recombinant thrombopoietic agents. He has illuminated genetic polymorphisms, cytokine signaling pathways, and immune dysregulation mechanisms underlying chronic immune thrombocytopenia. His contributions further extend to leukemogenesis, epigenetic alterations in hematologic malignancies, and therapeutic optimization in refractory leukemia. As an active member of national and international hematology societies, he leads major funded research projects and has been recognized with multiple scientific achievement awards, reflecting his broad impact on hematologic innovation and patient-centered clinical advancement.

Profile: Scopus

Featured Publications

1. Zhou, H., et al. (2025). Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): A multicenter, single-arm, phase III trial. Clinical and Experimental Medicine.

2. Zhou, H., et al. (2025). Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: Multicentre, randomised, placebo-controlled, phase 2 trial. BMJ Clinical Research Edition.

3. Zhou, H., et al. (2025). Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study. Cancer.

4. Zhou, H., et al. (2025). Hetrombopag for patients with persistent primary immune thrombocytopenia: A post hoc analysis of a multicenter, randomized phase III trial. Research and Practice in Thrombosis and Haemostasis.

5. Zhou, H., et al. (2025). Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: A multicenter, randomised controlled trial (The TE-ITP Study). EClinicalMedicine.

Shubham Gupta | Transfusion Medicine | Young Scientist Award

Published on by Global Academic Awards

Dr. Shubham Gupta | Transfusion Medicine | Young Scientist Award

Dr. Shubham Gupta, Medanta, India

Dr. Shubham Gupta is a Senior Resident in Immunohematology & Transfusion Medicine at Medanta – The Medicity, Gurugram, Haryana. He completed his DNB in Immunohematology & Transfusion Medicine and MBBS from Major S.D. Singh Medical College, Farrukhabad. With expertise in therapeutic procedures like plasma exchange, leukapheresis, and CAR-T cell therapy, Dr. Gupta has contributed to several publications on transfusion medicine and hematology. He has presented at numerous national conferences and participated in webinars on oncology, hematology, and blood transfusion. He holds memberships with ISTM, BBTS, ISBT, and SPCTT. 🩸💉

Publication Profile

Scopus

Education

Dr. Shubham Gupta is an expert in Immunohematology & Transfusion Medicine, currently serving as a Senior Resident at Medanta – The Medicity, Gurugram, Haryana. He completed his DNB in Immunohematology & Transfusion Medicine from Medanta and his MBBS from Major S.D. Singh Medical College & Hospital, Farrukhabad, Uttar Pradesh. Dr. Gupta is registered with both the Medical Council of Uttar Pradesh and the Haryana Medical Council. His work focuses on cutting-edge therapies like plasma exchange, leukapheresis, and CAR-T cell therapy, contributing significantly to the field of transfusion medicine and hematology. 💉

Professional Experience

Dr. Shubham Gupta has gained diverse clinical experience over the years. From June 2017 to July 2018, he worked for a year in the Department of Ophthalmology and Emergency Services at Government Doon Medical College, Dehradun, Uttarakhand. He then pursued his DNB residency in Immunohematology & Transfusion Medicine at Medanta – The Medicity, Gurugram, from June 2019 to July 2022, further strengthening his expertise. Since August 2022, he has been serving as a Senior Resident in the same department at Medanta, specializing in advanced transfusion therapies and hematology techniques. 💉👨‍⚕️

Certificate Courses 🎓

Dr. Shubham Gupta has pursued several specialized certificate courses to enhance his expertise in the medical field. These include the ICMR Basic Course in Biomedical Research, the ICMR Basic Course in Vector-Borne Diseases for Health Professionals, and a Certificate Course in Patient Blood Management (PBM). He has also completed the Good Clinical Practice (GCP) Certificate Course. Additionally, Dr. Gupta is trained in LIFECODES SS-OHLA Typing on the LUMINEX Analyzer and holds a certification from the National HIV Curriculum, an AIDS Education and Training Center Program by the University of Washington. 📚💉

Academic Courses & Teaching 📚

Dr. Shubham Gupta has been actively involved in academic programs to foster excellence in medical education. He has participated in the Post-graduate (DNB) Teaching Program organized by the National Board of Examination (NBE). He also completed the Clinical Excellence Program for Medical Officers (M.O.) at Medanta – The Medicity, honing his clinical skills and knowledge. Additionally, Dr. Gupta is certified in the Bone Marrow Transplant (BMT) Nursing Specialty Course, further enhancing his expertise in hematology and stem cell transplantation. These academic courses reflect his commitment to ongoing education and professional development. 🎓

Research Focus 🔬

Dr. Shubham Gupta’s research primarily focuses on Hematopoietic Progenitor Cells (HPC), particularly their infusion and adverse reactions in patients undergoing stem cell therapies, as demonstrated in his work on real-world evidence of adverse reactions to thawed HPC infusion. This research aims to understand the safety and effectiveness of these therapies in clinical settings, contributing to transfusion medicine and hematology. His work is critical for improving bone marrow transplantation (BMT) and stem cell therapies. Dr. Gupta’s research also spans areas of patient blood management (PBM) and immune response in hematology. 🧬💉

Publication Top Notes

Real-World Evidence Data on Adverse Reactions to Infusion of Thawed Hematopoietic Progenitor Cells: Retrospective Analysis from a Single Center in India